U.S. markets close in 5 hours 11 minutes
  • S&P 500

    -33.87 (-0.83%)
  • Dow 30

    -210.96 (-0.61%)
  • Nasdaq

    -95.92 (-0.84%)
  • Russell 2000

    -35.48 (-1.87%)
  • Crude Oil

    +0.51 (+0.64%)
  • Gold

    -21.30 (-1.18%)
  • Silver

    -0.69 (-2.97%)

    +0.0010 (+0.09%)
  • 10-Yr Bond

    +0.0910 (+2.60%)

    -0.0075 (-0.61%)

    +1.9150 (+1.43%)

    +73.85 (+0.43%)
  • CMC Crypto 200

    -7.17 (-1.74%)
  • FTSE 100

    +21.88 (+0.29%)
  • Nikkei 225

    +42.50 (+0.15%)

Gene Therapy Market worth $17.2 billion by 2027 – Exclusive Report by MarketsandMarkets™

MarketsandMarkets Research Pvt. Ltd.
MarketsandMarkets Research Pvt. Ltd.

Chicago, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gene Therapy Market is projected to grow from USD 7.3 billion in 2022 to USD 17.2 billion by 2027, at a CAGR of 18.6% from 2022 to 2027, according to a new report by MarketsandMarkets™. Factors such as growing cases of cancer and neurological diseases, rising gene therapy product approvals, and increasing investment in research and development of gene therapies will drive the market growth. However, factors such as high cost associated with gene therapy are restraining the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

Browse in-depth TOC on “Gene Therapy Market
165 – Tables
33 – Figures
159 – Pages

The non-viral vectors segment accounted for the largest share in the gene therapy market, by vector, during the forecast period.

Based on vectors, the market is segmented into non-viral vectors and viral vectors. Non-viral vectors accounted for the larger market share in 2021. Less immunogenicity than viral vectors coupled with easier mass production of non-viral vectors are the major factors driving the growth of this segment.

The Neurological diseases segment accounted for the largest share of the indication segment in the gene therapy market in 2021.

Based on indication, the market is segmented into neurological diseases, cancer, duchenne muscular dystrophy, hepatological diseases, and other indications. The neurological diseases segment accounted for the largest share of the market in 2021. The largest share is attributed to growing burden of neurological diseases coupled with rising adoption of gene therapy for the treatment of neurological disorders.

The in vivo segment accounted for the larger share of the delivery method segment in the gene therapy market in 2021.

On the basis of delivery method, the market is segmented into in vivo and ex vivo. In vivo segment accounted for the larger share in the market as majority of the approved gene therapy products fall under in vivo delivery method.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962

North America is the largest region and Asia Pacific is the fastest-growing region of the gene therapy market in 2021.

Based on region, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2021, North America dominated the market, followed by Europe. The significant government and private investments to develop advanced gene therapy products, the growing adoption rate of these products, and the presence of key market players in the region are responsible for the large share of North America in the market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

Key players in the gene therapy market include:

  1. Biogen (US),

  2. Novartis AG (Switzerland),

  3. Gilead Sciences Inc. (US), and

  4. Sarepta Therapeutics (US)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962

Browse Adjacent Market: Biotechnology Market Research Reports & Consulting

Related Reports:

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

CONTACT: About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com